These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 34557195)

  • 21. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.
    Zhu W; Liu H; Zhang X
    ACS Infect Dis; 2019 May; 5(5):703-712. PubMed ID: 30907080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
    Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
    J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    J Infect; 2014 Jul; 69(1):81-7. PubMed ID: 24631900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
    Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
    J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment.
    Yin GQ; Chen KP; Gu XC
    World J Gastroenterol; 2022 Oct; 28(40):5784-5800. PubMed ID: 36353205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
    Seo Y; Yano Y
    World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.
    Chen J; Wang Y; Wu XJ; Li J; Hou FQ; Wang GQ
    World J Gastroenterol; 2010 Dec; 16(48):6145-50. PubMed ID: 21182232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.
    Yeh ML; Huang JF; Yu ML; Chuang WL
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):427-435. PubMed ID: 33338385
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatitis B: future curative strategies.
    Bertoletti A; Rivino L
    Curr Opin Infect Dis; 2014 Dec; 27(6):528-34. PubMed ID: 25304392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    Wu W; Wu D; Yan W; Wang Y; You J; Wan X; Xi D; Luo X; Han M; Ning Q
    J Infect Dis; 2021 Feb; 223(4):686-698. PubMed ID: 32663850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress.
    Guo P
    Scand J Immunol; 2013 Sep; 78(3):230-7. PubMed ID: 23790137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.
    Pagliaccetti NE; Robek MD
    J Interferon Cytokine Res; 2010 Aug; 30(8):585-90. PubMed ID: 20645875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.